Applied DNA Sciences Inc. (now known as BNB Plus Corp.) reported a significant shift in its business strategy and financial performance in its recent 10-K filing. For the fiscal year ending September 30, 2025, the company generated total revenues of $2.14 million, a 5% increase from $2.03 million in the previous fiscal year. This growth was primarily driven by a 33% increase in product revenues, which rose to $1.42 million, largely attributed to increased shipments in its Therapeutic DNA Production Services segment. However, service revenues fell by 31% to $712,788, reflecting a decline in demand for certain services, particularly in the DNA Tagging and Security Products segment.
The company has undergone substantial restructuring, including a workforce reduction of approximately 72% since early 2025, aimed at focusing resources on its new digital asset treasury strategy centered around BNB, the native cryptocurrency of the Binance blockchain. This strategic pivot was initiated following the completion of a private placement in October 2025, which raised $26.8 million in cash and cryptocurrency assets, with the potential for an additional $30.8 million from future warrant exercises. The company is now concentrating on accumulating BNB and utilizing it as a productive treasury asset to generate yield through various decentralized finance opportunities.
Operationally, the company has made significant changes, including the formation of new subsidiaries, Build & Build, LLC and BNBX Ltd., to manage its cryptocurrency assets. As of December 15, 2025, Applied DNA Sciences reported holding approximately 18,830 BNB tokens, reflecting a strategic investment of around $3 million in BNB at an average price of $895 per token. The company’s workforce has been reduced to 13 employees, with a focus on enhancing its nucleic acid production capabilities through its LineaRx subsidiary, which is expected to continue generating revenue from product sales.
Despite these developments, the company faces challenges, including a material weakness in its internal controls over financial reporting, which could impact investor confidence. The filing also highlighted the inherent risks associated with the cryptocurrency market, including regulatory uncertainties and the volatility of digital asset prices, which could adversely affect the company's financial condition and stock price. Looking ahead, the company aims to leverage its BNB treasury strategy to enhance its financial position, although it acknowledges the potential for significant fluctuations in earnings due to the volatile nature of digital assets.
About APPLIED DNA SCIENCES INC
Applied DNA Sciences, Inc. is a biotechnology company specializing in the production and detection of DNA and RNA. Its key offerings include Therapeutic DNA Production Services, molecular diagnostics, and DNA tagging for supply chain security. With a focus on expanding its mRNA therapeutic capabilities, the company targets pharmaceutical developers and healthcare providers. Recent initiatives include launching a new IVT platform and expanding pharmacogenomics testing services, addressing significant market opportunities in biotechnology.
About 10-K Filings
A 10-K form is a comprehensive annual report that public companies in the United States must file with the SEC, providing a detailed overview of the company's financial condition, performance, and business strategies.
Key points about the 10-K:
- Frequency: Filed annually, typically within 60 to 90 days after the end of the company's fiscal year.
-
Content: It includes:
- Detailed financial statements audited by an independent accounting firm
- Management's Discussion and Analysis (MD&A) of financial condition and results
- Description of the company's business, properties, and legal proceedings
- Risk factors and market risks
- Executive compensation and corporate governance information
- Importance: Considered the most comprehensive and important document a public company files with the SEC.
- Length: Often exceeds 100 pages due to its extensive and detailed nature.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.